AGEN Stock Forecast 2025-2026
Distance to AGEN Price Targets
AGEN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Agenus (AGEN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AGEN and similar high-potential opportunities.
Latest AGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, AGEN has a neutral consensus with a median price target of $7.00 (ranging from $3.00 to $11.00). The overall analyst rating is Buy (6.8/10). Currently trading at $1.86, the median forecast implies a 276.3% upside. This outlook is supported by 1 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Colleen Kusy at Baird, suggesting a 61.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AGEN Analyst Ratings
AGEN Price Target Range
Latest AGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Baird | Colleen Kusy | Neutral | Maintains | $3.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $0.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $0.00 |
| Dec 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $0.00 |
| Nov 29, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $7.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $7.00 |
| Aug 14, 2024 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $18.00 |
| Jul 19, 2024 | Jefferies | Biren Amin | Hold | Downgrade | $7.00 |
| Jul 18, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $9.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $40.00 |
| May 24, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $40.00 |
| May 7, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $40.00 |
| Mar 18, 2024 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $5.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $8.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Jul 3, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $8.30 |
| Jul 3, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Jun 6, 2023 | Baird | Outperform | Initiates | $0.00 | |
| Jun 5, 2023 | EF Hutton | Buy | Reiterates | $0.00 | |
| Jun 5, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 |
Agenus Inc. (AGEN) Competitors
The following stocks are similar to Agenus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agenus Inc. (AGEN) Financial Data
Agenus Inc. has a market capitalization of $43.92M with a P/E ratio of 0.5x. The company generates $160.43M in trailing twelve-month revenue with a -141.9% profit margin.
Revenue growth is +3.3% quarter-over-quarter, while maintaining an operating margin of -132.9% and return on equity of +165.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Agenus Inc. (AGEN) Business Model
About Agenus Inc.
Develops immunotherapy products for cancer treatment.
Agenus Inc. generates revenue by developing and commercializing innovative immunotherapy products, including antibody-based therapeutics and vaccine adjuvants. The company leverages its proprietary technologies, such as Retrocyte Display, to enhance the efficiency of antibody discovery and optimize therapeutic candidates, targeting various cancer types.
Agenus is actively involved in the advancement of personalized medicine and plays a significant role in the biopharmaceutical sector. Its focus on checkpoint inhibitors and a diverse pipeline positions the company to address unmet medical needs and contribute to the development of breakthrough cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
389
CEO
Dr. Garo H. Armen Ph.D.
Country
United States
IPO Year
2000
Website
www.agenusbio.comAgenus Inc. (AGEN) Latest News & Analysis
Agenus Inc. (NASDAQ: AGEN) will hold its Q4 2024 earnings conference call on March 11, 2025, at 8:30 AM ET, featuring key executives and analysts from H.C. Wainwright.
Agenus Inc.'s upcoming earnings call could reveal key financial results and strategic updates, influencing stock performance and investor sentiment.
Agenus Inc. reported Q4 and full-year 2024 results, noting a significant reduction in operational costs while focusing on its BOT/BAL program. The company aims to lower its annualized burn rate.
Agenus Inc.'s cost reduction and focus on its BOT/BAL program may enhance financial stability and growth potential, impacting investor sentiment and stock performance positively.
Agenus (AGEN) reported a quarterly loss of $2.04 per share, better than the Zacks estimate of $2.36, and improved from a loss of $2.60 per share a year prior.
Agenus reported a smaller quarterly loss than expected, indicating potential operational improvements. Year-over-year loss reduction may boost investor confidence and stock performance.
Agenus Inc. (Nasdaq: AGEN) will release its Q4 and year-end 2024 financial results on March 11, 2024, before market open, followed by a conference call at 8:30 a.m. ET.
Agenus' upcoming financial results and corporate update could impact stock performance, reflecting progress in cancer treatment and influencing investor sentiment in the biotech sector.
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
20 days agoAgenus Inc. (Nasdaq: AGEN) presented data at the AACR meeting on its Phase 2 study of botensilimab and balstilimab combined with agenT-797, an iNKT therapy.
Agenus Inc.'s presentation at a major cancer conference showcases promising data for its therapies, potentially influencing stock performance and attracting investor interest in immuno-oncology.
Agenus Inc. (Nasdaq: AGEN) is advancing its clinical pipeline in cancer immunotherapy, focusing on checkpoint inhibitors, immune activators, and cell therapies through MiNK Therapeutics.
Agenus Inc.'s advancements in cancer immunotherapy and strong clinical pipeline could enhance its market position, potentially leading to increased investor confidence and stock value.
Frequently Asked Questions About AGEN Stock
What is Agenus Inc.'s (AGEN) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Agenus Inc. (AGEN) has a median price target of $7.00. The highest price target is $11.00 and the lowest is $3.00.
Is AGEN stock a good investment in 2025?
According to current analyst ratings, AGEN has 1 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AGEN stock?
Wall Street analysts predict AGEN stock could reach $7.00 in the next 12 months. This represents a 276.3% increase from the current price of $1.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agenus Inc.'s business model?
Agenus Inc. generates revenue by developing and commercializing innovative immunotherapy products, including antibody-based therapeutics and vaccine adjuvants. The company leverages its proprietary technologies, such as Retrocyte Display, to enhance the efficiency of antibody discovery and optimize therapeutic candidates, targeting various cancer types.
What is the highest forecasted price for AGEN Agenus Inc.?
The highest price target for AGEN is $11.00 from at , which represents a 491.4% increase from the current price of $1.86.
What is the lowest forecasted price for AGEN Agenus Inc.?
The lowest price target for AGEN is $3.00 from Colleen Kusy at Baird, which represents a 61.3% increase from the current price of $1.86.
What is the overall AGEN consensus from analysts for Agenus Inc.?
The overall analyst consensus for AGEN is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are AGEN stock price projections?
Stock price projections, including those for Agenus Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
